Trial Profile
A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant (Primary) ; Exemestane
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms SoFEA
- 27 Jul 2022 Status changed from active, no longer recruiting to completed.
- 16 Jun 2020 Results, a pooled analysis of the phase III SoFEA and EFECT trials, published in the Clinical Cancer Research
- 08 Sep 2013 Results published in Lancet Oncology, according to an Institute of Cancer Research media release.